secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0000950170-23-029599
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS terminates $35M loan with Hercules/SVB after GSK deal; receives $25M milestone; clarifies equity vote
--------------------------------------------------------------------------------

- Terminated $35M Loan and Security Agreement with Hercules Capital and SVB on May 25, 2023, after receiving upfront payment from GSK license.
- Announced $25M performance milestone from GSK on June 21, 2023, for Phase 3 MARIO study of ibrexafungerp.
- Due to proxy statement ambiguity on broker non-votes, SCYNEXIS deemed 2023 Equity Incentive Plan vote not approved; will use 2014 plan and reintroduce in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000095017023029599/0000950170-23-029599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000095017023029599/scyx-20230525.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer